Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
PHEX gene mutations sit on the X chromosome and cause X-linked hypophosphatemia (XLH) in a dominant pattern, meaning an affected father passes the variant to all of his daughters and none of his sons, an affected mother has a 50% chance of passing it to each child, and roughly one in three cases arise from a new spontaneous mutation with no family history. When PHEX stops working, levels of the hormone FGF23 climb, which blocks phosphate reabsorption in the kidney's proximal tubules and suppresses active vitamin D, so phosphate leaks into the urine instead of building bone and dental enamel. The result can include bowed legs, slowed growth, bone and joint pain, dental abscesses, and hearing changes, though severity varies widely even among relatives who carry the identical variant. Several important factors influence how this presents and what testing confirms it, including lab patterns, age of onset, and inheritance risk for children, so review the complete details below before drawing conclusions.
If low phosphate, bone pain, unusual leg curvature, or repeated dental problems sound familiar in you or your child, guessing wastes time that growing bones cannot spare, and a free, instant, online symptom check can help you organize your symptoms, see which conditions may fit, and understand which specialist or lab work to ask for next.
Last reviewed for medical accuracy: 08/18/2026
X-linked hypophosphatemic rickets (XLH) is the most common form of inherited rickets, affecting about 1 in 20,000 people. At its heart lies a problem with the PHEX gene, which leads to too much phosphate being lost through the kidneys. In this article, we’ll explain the role of PHEX, how mutations trigger phosphate leaks, and what this means for families navigating XLH genetics.
Phosphate is a mineral critical for:
When phosphate levels drop, bones can become soft and weak—a condition known as rickets in children and osteomalacia in adults.
PHEX (phosphate-regulating endopeptidase homolog, X-linked) is a gene on the X chromosome that encodes an enzyme involved in regulating proteins called fibroblast growth factors (FGFs). In particular, FGF23 is a hormone that tells the kidneys to excrete phosphate. Under normal conditions:
When there’s a mutation in PHEX:
XLH genetics follows an X-linked dominant pattern. Here’s what that means:
• Affected gene is on the X chromosome
• Females (XX) need only one mutated copy to be affected
• Males (XY) will be affected if their single X chromosome has the mutation
• Each child of an affected mother has a 50% chance of inheriting the mutation
• Each child of an affected father:
Because males have only one X chromosome, they often show more severe symptoms. However, females can also experience significant bone and dental issues.
Symptoms and severity can vary, even within the same family. Common manifestations include:
• Poor growth and short stature
• Bowed legs or knock knees
• Bone pain and tenderness
• Dental abscesses (due to defective dentin)
• Muscle weakness and fatigue
• Bone fractures, especially in adolescence
Lab findings often show:
Diagnosis typically involves:
Early recognition and treatment help improve growth outcomes and reduce complications.
While there is no cure for XLH, several approaches help manage phosphate loss and support bone health.
Regular follow-up with an endocrinologist and nephrologist is crucial to adjust treatment and monitor for side effects, such as secondary hyperparathyroidism.
Living with an inherited condition calls for a proactive, multidisciplinary approach:
• Maintain a balanced diet rich in calcium and protein.
• Schedule regular bone density scans.
• Keep consistent with medication and supplement schedules.
• Engage in low-impact exercises like swimming, which support bone strength without overloading joints.
• Seek psychosocial support or peer groups for families affected by XLH.
If you or a family member has symptoms such as persistent bone pain, difficulty walking, or unusual bone shapes, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. Early evaluation can guide timely testing for XLH and related conditions.
Always speak to a doctor about anything that could be life-threatening or seriously impact your health. Genetic counseling is also recommended for families planning children, to fully understand inheritance risks and options.
Research continues into:
Advances in understanding XLH genetics promise better outcomes and quality of life for those affected.
X-linked hypophosphatemic rickets XLH genetics may sound complex, but knowing how PHEX mutations drive phosphate loss empowers families and clinicians to take action. With current treatments and ongoing research, many individuals with XLH lead active, fulfilling lives. If you suspect XLH in yourself or a loved one, start with a symptom check and speak to your healthcare provider about testing and treatment options.
(References)
* Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, AXLES 1 Investigators. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. PMID: 29947083.
* Christov M, Jüppner H. Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):685-706. doi: 10.1016/j.beem.2018.06.004. Epub 2018 Jun 18. PMID: 30449549.
* Bitzan M, Goodyer PR. Hypophosphatemic Rickets. Pediatr Clin North Am. 2019 Feb;66(1):179-207. doi: 10.1016/j.pcl.2018.09.004. PMID: 30454743.
* Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019 Jun 15;393(10189):2416-2427. doi: 10.1016/S0140-6736(19)30654-3. Epub 2019 May 16. PMID: 31104833; PMCID: PMC7179969.
* Rush ET, Johnson B, Aradhya S, Beltran D, Bristow SL, Eisenbeis S, Guerra NE, Krolczyk S, Miller N, Morales A, Ramesan P, Sarafrazi S, Truty R, Dahir K. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. J Bone Miner Res. 2022 Feb;37(2):202-214. doi: 10.1002/jbmr.4454. Epub 2021 Nov 10. PMID: 34633109; PMCID: PMC9298723.
* Miller WL, Imel EA. Rickets, Vitamin D, and Ca/P Metabolism. Horm Res Paediatr. 2022;95(6):579-592. doi: 10.1159/000527011. Epub 2022 Nov 29. PMID: 36446330.
* Kamenický P, Briot K, Munns CF, Linglart A. X-linked hypophosphataemia. Lancet. 2024 Aug 31;404(10455):887-901. doi: 10.1016/S0140-6736(24)01305-9. Epub 2024 Aug 21. PMID: 39181153.
* Haffner D, Emma F, Seefried L, Högler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Biosse Duplan M, Schnabel D, Wicart P, Ariceta G, Levtchenko E, Harvengt P, Kirchhoff M, Gardiner O, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenický P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2025 May;21(5):330-354. doi: 10.1038/s41581-024-00926-x. Epub 2025 Jan 15. PMID: 39814982.
* Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Cohen-Solal M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Ward LM, Guyatt G, Brandi ML. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jul 15;110(8):2353-2370. doi: 10.1210/clinem/dgaf170. PMID: 40243526; PMCID: PMC12261105.
* Böckmann I, Haffner D. The Diagnosis and Therapy of XLH. Calcif Tissue Int. 2025 Apr 28;116(1):66. doi: 10.1007/s00223-025-01374-w. Epub 2025 Apr 28. PMID: 40295317; PMCID: PMC12037658.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.